Gene Therapy for Diabetes
糖尿病基因治疗
基本信息
- 批准号:10239013
- 负责人:
- 金额:$ 72.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-20 至 2023-07-31
- 项目状态:已结题
- 来源:
- 关键词:3&apos Untranslated RegionsAcinar CellAllogenicAlpha CellBar CodesBeta CellBinding SitesBiodistributionBioinformaticsBlood GlucoseCapsidCell TransplantationCellsChemicalsChronicClinicalDataDatabasesDependovirusDevelopmentDiabetes MellitusDirected Molecular EvolutionDiseaseDisease ManagementDoseDrug KineticsDuct (organ) structureDuctal Epithelial CellElementsEndocrineEndoderm CellEndoscopic Retrograde CholangiopancreatographyEnhancersEvolutionGastroenterologyGene DeliveryGene ExpressionGene Transduction AgentGeneral PopulationGenetic TranscriptionGoalsGrantHumanIn SituIndividualInjectionsInsulinInsulin-Dependent Diabetes MellitusIslet CellIslets of LangerhansLibrariesMacaca mulattaMediatingMethodsMicroRNAsMolecularMusNatural regenerationPancreasPancreatic ductPatientsPremature MortalityPrimatesProceduresPropertyReagentRegulatory ElementReporterReporter GenesRodentRouteSafetySiteSpecificityStructure of alpha Cell of isletSystemTechnologyTherapeuticTransplantationTropismVariantViral VectorVirusWorkadeno-associated viral vectoraptamerbasebeta cell replacementcell typeclinical applicationclinical translationdiabetes mellitus therapygene therapygenetic payloadhumanized mousein vivoinnovationisletmouse modelnonhuman primatenovelpre-clinicalpromoterside effectstem cellstranscription factortransduction efficiencytransgene expressionunnatural amino acidsvector
项目摘要
PROJECT SUMMARY
Two potential approaches exist for the replacement of the β-cells lost in type 1 diabetes (T1D). The first is to
transplant new β-cells derived from either allogeneic pancreas donors or stem cells. The second approach is to
generate new β-cells in situ in the T1D patient without any need for cell transplantation. This can be achieved
by transcription factor mediated reprogramming of endodermal cell types related to β-cells. Gene therapy
vectors are used to deliver the reprogramming factors.
We and others have recently found that it is possible to correct diabetes in mice by retrograde ductal
injection of reprogramming vectors. Intraductal delivery has the advantage of delivering a high dose of gene
therapy vector locally, minimizing systemic side effects and achieving a high local concentration of
reprogramming factors. Furthermore, this route of administration is readily feasible in humans, as ERCP
(endoscopic retrograde cholangio-pancreatography) is a routine procedure in clinical gastroenterology.
Preclinical work in rodents indicates that α-cells are the prime target for reprogramming, while
pancreatic ducts may also be converted to functional β-like cells.
In this proposal, we will develop AAV vectors that are optimized for reprogramming the α-cells of
humans and non-human primates to the β-cell fate after intraductal delivery. We are building on the progress
made in our current HIRN UC4 grant, in which we developed novel AAV capsids capable of transducing
human endocrine cells with high efficiency. We also evolved cis-regulatory elements (CREs) capable of
restricting transgene expression to only β-cells.
In Aim 1, we will produce novel AAV capsids (variants) that are highly efficient in transducing pancreatic
α-cells and duct cells after retrograde injection in non-human primates in vivo. Highly innovative capsid
evolution methods will be used. In Aim 2, we will generate CREs that direct transgene expression specifically
to the reprogramming target, i.e. α-cells. Cell-type specific promoters will be combined with microRNA
recognition elements to achieve this goal. Finally, in Aim 3, AAV capsids generated by Aim 1 and CREs
developed in Aim 2 will be combined to produce optimized AAV capable of delivering reprogramming factors to
α-cells and its capability of reprogramming will be assessed in non-human primates.
Successful execution of this work will generate the preclinical data needed to determine whether this
approach has potential for clinical application in humans.
项目概要
有两种潜在的方法可以替代 1 型糖尿病 (T1D) 中丢失的 β 细胞。第一个是
移植来自同种异体胰腺供体或干细胞的新 β 细胞。第二种方法是
在 T1D 患者体内原位产生新的 β 细胞,无需任何细胞移植。这是可以实现的
通过转录因子介导的与 β 细胞相关的内胚层细胞类型的重编程。基因治疗
载体用于传递重编程因子。
我们和其他人最近发现可以通过逆行导管来纠正小鼠的糖尿病
注射重编程载体。导管内递送具有递送高剂量基因的优点
局部治疗载体,最大限度地减少全身副作用并实现高局部浓度
重编程因素。此外,这种给药途径在人类中很容易实现,因为 ERCP
(内镜逆行胰胆管造影)是临床胃肠病学的常规手术。
啮齿动物的临床前工作表明 α 细胞是重编程的主要目标,而
胰管也可能转化为功能性β样细胞。
在本提案中,我们将开发 AAV 载体,该载体经过优化,可以对 α 细胞进行重编程
人类和非人类灵长类动物导管内分娩后β细胞的命运。我们正在取得进展
我们目前的 HIRN UC4 资助项目中,我们开发了能够转导的新型 AAV 衣壳
人体内分泌细胞效率高。我们还进化了顺式调控元件(CRE),能够
将转基因表达仅限于 β 细胞。
在目标 1 中,我们将生产能够高效转导胰腺的新型 AAV 衣壳(变体)
非人灵长类动物体内逆行注射后的α细胞和导管细胞。高度创新的衣壳
将使用进化方法。在目标 2 中,我们将生成专门指导转基因表达的 CRE
到重编程目标,即α细胞。细胞类型特异性启动子将与microRNA结合
实现这一目标的识别要素。最后,在目标 3 中,目标 1 和 CRE 生成的 AAV 衣壳
Aim 2中开发的AAV将被结合起来产生优化的AAV,能够将重编程因子传递给
α细胞及其重编程能力将在非人类灵长类动物中进行评估。
这项工作的成功执行将生成确定该药物是否有效所需的临床前数据。
该方法具有在人类临床应用的潜力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Markus Grompe其他文献
Markus Grompe的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Markus Grompe', 18)}}的其他基金
In vivo targeting of diabetes-relevant human cell types with rAAV vectors
rAAV 载体体内靶向糖尿病相关人类细胞类型
- 批准号:
8812513 - 财政年份:2014
- 资助金额:
$ 72.09万 - 项目类别:
相似海外基金
Impact of alternative polyadenylation of 3'-untranslated regions in the PI3K/AKT cascade on microRNA
PI3K/AKT 级联中 3-非翻译区的替代多聚腺苷酸化对 microRNA 的影响
- 批准号:
573541-2022 - 财政年份:2022
- 资助金额:
$ 72.09万 - 项目类别:
University Undergraduate Student Research Awards
How do untranslated regions of cannabinoid receptor type 1 mRNA determine receptor subcellular localisation and function?
1 型大麻素受体 mRNA 的非翻译区如何决定受体亚细胞定位和功能?
- 批准号:
2744317 - 财政年份:2022
- 资助金额:
$ 72.09万 - 项目类别:
Studentship
MICA:Synthetic untranslated regions for direct delivery of therapeutic mRNAs
MICA:用于直接递送治疗性 mRNA 的合成非翻译区
- 批准号:
MR/V010948/1 - 财政年份:2021
- 资助金额:
$ 72.09万 - 项目类别:
Research Grant
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10019570 - 财政年份:2019
- 资助金额:
$ 72.09万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10223370 - 财政年份:2019
- 资助金额:
$ 72.09万 - 项目类别:
Translational Control by 5'-untranslated regions
5-非翻译区域的翻译控制
- 批准号:
10455108 - 财政年份:2019
- 资助金额:
$ 72.09万 - 项目类别:
Synergistic microRNA-binding sites, and 3' untranslated regions: a dialogue of silence
协同的 microRNA 结合位点和 3 非翻译区:沉默的对话
- 批准号:
255762 - 财政年份:2012
- 资助金额:
$ 72.09万 - 项目类别:
Operating Grants
Analysis of long untranslated regions in Nipah virus genome
尼帕病毒基因组长非翻译区分析
- 批准号:
20790351 - 财政年份:2008
- 资助金额:
$ 72.09万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Search for mRNA elements involved in the compatibility between 5' untranslated regions and coding regions in chloroplast translation
寻找参与叶绿体翻译中 5 非翻译区和编码区之间兼容性的 mRNA 元件
- 批准号:
19370021 - 财政年份:2007
- 资助金额:
$ 72.09万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Post-transcriptional Regulation of PPAR-g Expression by 5'-Untranslated Regions
5-非翻译区对 PPAR-g 表达的转录后调控
- 批准号:
7131841 - 财政年份:2006
- 资助金额:
$ 72.09万 - 项目类别: